Evaluating the effectiveness and safety of AD-224 for treating essential hypertension
A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients with Essential Hypertension
This study is testing a new medication called AD-224 to see if it can safely lower blood pressure in people with essential hypertension.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 252 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Addpharma Inc. Industry-sponsored |
| Locations | 1 site (Seongnam-si) |
| Trial ID | NCT06291207 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the efficacy and safety of a new medication, AD-224, in patients diagnosed with essential hypertension. Participants will receive either AD-224 in various formulations or a placebo to determine the drug's effectiveness in lowering blood pressure. The study will involve monitoring patient responses and any adverse effects over a specified period. The goal is to establish whether AD-224 can provide a safe and effective treatment option for individuals with this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with essential hypertension who can provide informed consent.
Not a fit: Patients with secondary hypertension will not benefit from this study as it specifically targets essential hypertension.
Why it matters
Potential benefit: If successful, this study could offer a new treatment option for patients suffering from essential hypertension.
How similar studies have performed: Other studies evaluating similar antihypertensive medications have shown promising results, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed informed consent * Patients with Essential Hypertension * Other inclusions applied Exclusion Criteria: * Patient with Secondary Hypertension * Other exclusions applied
Where this trial is running
Seongnam-si
- Seoul National University Bundang Hospital — Seongnam-si, South Korea (Recruiting)
Study contacts
- Principal investigator: InHo Chae, M.D., Ph.D — Seoul National University Bundang Hospital
- Study coordinator: JeongEun Park
- Email: parkje@addpharma.co.kr
- Phone: +82-31-891-6989
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.